Compare VENUS REMEDIES with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES UNICHEM LAB VENUS REMEDIES/
UNICHEM LAB
 
P/E (TTM) x -1.1 61.3 - View Chart
P/BV x 0.1 0.7 11.1% View Chart
Dividend Yield % 0.0 2.1 -  

Financials

 VENUS REMEDIES   UNICHEM LAB
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
UNICHEM LAB
Mar-19
VENUS REMEDIES/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs126292 43.1%   
Low Rs61182 33.6%   
Sales per share (Unadj.) Rs301.8167.7 180.0%  
Earnings per share (Unadj.) Rs-24.9-3.6 685.0%  
Cash flow per share (Unadj.) Rs2.55.9 42.8%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %01.7 0.0%  
Book value per share (Unadj.) Rs293.3372.3 78.8%  
Shares outstanding (eoy) m12.3470.38 17.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.31.4 21.9%   
Avg P/E ratio x-3.8-65.3 5.8%  
P/CF ratio (eoy) x36.739.9 92.1%  
Price / Book Value ratio x0.30.6 50.1%  
Dividend payout %0-110.2 0.0%   
Avg Mkt Cap Rs m1,15416,680 6.9%   
No. of employees `0000.92.6 35.5%   
Total wages/salary Rs m3932,393 16.4%   
Avg. sales/employee Rs Th4,026.14,535.2 88.8%   
Avg. wages/employee Rs Th425.0919.8 46.2%   
Avg. net profit/employee Rs Th-331.8-98.2 337.8%   
INCOME DATA
Net Sales Rs m3,72411,801 31.6%  
Other income Rs m23984 2.3%   
Total revenues Rs m3,74712,785 29.3%   
Gross profit Rs m395-835 -47.3%  
Depreciation Rs m338674 50.2%   
Interest Rs m35475 471.1%   
Profit before tax Rs m-275-600 45.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32-343 -9.2%   
Profit after tax Rs m-307-256 120.1%  
Gross profit margin %10.6-7.1 -149.8%  
Effective tax rate %-11.557.3 -20.0%   
Net profit margin %-8.2-2.2 380.6%  
BALANCE SHEET DATA
Current assets Rs m2,63820,384 12.9%   
Current liabilities Rs m2,3055,029 45.8%   
Net working cap to sales %8.9130.1 6.9%  
Current ratio x1.14.1 28.2%  
Inventory Days Days135105 129.3%  
Debtors Days Days46135 34.4%  
Net fixed assets Rs m4,8719,023 54.0%   
Share capital Rs m123141 87.6%   
"Free" reserves Rs m3,49626,058 13.4%   
Net worth Rs m3,61926,199 13.8%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50931,496 23.8%  
Interest coverage x0.2-7.0 -3.2%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.4 132.4%   
Return on assets %0.6-0.6 -110.3%  
Return on equity %-8.5-1.0 869.4%  
Return on capital %1.6-2.0 -79.1%  
Exports to sales %069.4 0.0%   
Imports to sales %13.90-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs m517NA-   
Fx inflow Rs m08,188 0.0%   
Fx outflow Rs m517596 86.7%   
Net fx Rs m-5177,592 -6.8%   
CASH FLOW
From Operations Rs m514-3,278 -15.7%  
From Investments Rs m-123-2,860 4.3%  
From Financial Activity Rs m-387-24 1,599.6%  
Net Cashflow Rs m4-4,690 -0.1%  

Share Holding

Indian Promoters % 32.9 50.1 65.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 15.1 1.2%  
FIIs % 0.6 3.0 19.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 31.7 209.5%  
Shareholders   20,121 20,176 99.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ELDER PHARMA  FDC LTD.  ORCHID PHARMA LTD  DISHMAN PHARMA  TTK HEALTHCARE  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Over 100 Points Down; Banking and IT Stocks Under Pressure(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.9% while the Hang Seng is also down 0.9%.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Sep 16, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS